- Home
- IMNM vs DX Comparison
IMNM vs DX Comparison
Compare IMNM & DX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | DX |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMNM | DX |
|---|---|---|
| Price | $22.66 | $14.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $31.22 | $13.83 |
| AVG Volume (30 Days) | 2.5M | ★ 6.0M |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 13.92% |
| EPS Growth | N/A | ★ 35.65 |
| EPS | N/A | ★ 1.66 |
| Revenue | $9,679,000.00 | ★ $230,447,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.53 | $134.14 |
| P/E Ratio | ★ N/A | $8.83 |
| Revenue Growth | N/A | ★ 87.09 |
| 52 Week Low | $5.15 | $10.79 |
| 52 Week High | $25.30 | $14.67 |
Technical Indicators
Market Signals| Indicator | IMNM | DX |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 76.15 |
| Support Level | $20.05 | $13.90 |
| Resistance Level | $22.01 | $14.13 |
| Average True Range (ATR) | 1.28 | 0.23 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 82.00 | 99.45 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.